Scholar Rock Holding Corporation Common Stock (SRRK) Stock
NASDAQ · SRRK
48.56
Fundamentals
Market cap
$5.92B
Price / Earnings ratio
-14.5x
Price / Sales ratio
N/A
Price / Book ratio
23.3x
Return on assets
-97.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NeutralSRRKSeptember 21, 2026
Business WireNeutral
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRRK

Stocktwits
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
NeutralSRRKSeptember 14, 2026
StocktwitsNeutral
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
SRRK

Reuters
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
NeutralSRRKSeptember 14, 2026
ReutersNeutral
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
SRRK

Stocktwits
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
NeutralSRRKSeptember 11, 2026
StocktwitsNeutral
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
SRRK
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy8
Strong Buy1
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
485M320M160M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-377.9M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NeutralSRRKSeptember 21, 2026
Business WireNeutral
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRRK

Stocktwits
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
NeutralSRRKSeptember 14, 2026
StocktwitsNeutral
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
SRRK

Reuters
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
NeutralSRRKSeptember 14, 2026
ReutersNeutral
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
SRRK

Stocktwits
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
NeutralSRRKSeptember 11, 2026
StocktwitsNeutral
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
SRRK

Business Wire
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
NeutralSRRKSeptember 11, 2026
Business WireNeutral
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
SRRK

Reuters
US FDA approves Scholar Rock's muscle weakness drug
NeutralSRRKSeptember 11, 2026
ReutersNeutral
US FDA approves Scholar Rock's muscle weakness drug
SRRK

Business Wire
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
NeutralSRRKSeptember 2, 2026
Business WireNeutral
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
SRRK

Business Wire
Scholar Rock to Present at Upcoming Investor Conferences
NeutralSRRKAugust 27, 2026
Business WireNeutral
Scholar Rock to Present at Upcoming Investor Conferences
SRRK

Stocktwits
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
NeutralSRRKAugust 21, 2026
StocktwitsNeutral
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
SRRK

Reuters
Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission
NeutralSRRKAugust 21, 2026
ReutersNeutral
Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission
SRRK
About Scholar Rock Holding Corporation Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees289
CEOMr. David L. Hallal
IPO DateMay 24, 2018
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. David L. Hallal | CEO & Chairman of the Board | 1966 |
| Mr. Vikas Sinha C.A., CPA, M.B.A. | CFO & Treasurer | 1963 |
| Mr. Robert Keith Woods | Chief Operating Officer | 1968 |
| Dr. Akshay Krishnadas Vaishnaw M.D., Ph.D. | President of R&D, Member of Scientific Advisory Board and Director | 1963 |
| Ms. Erin Moore CPA | Interim Principal Financial & Accounting Officer | 1975 |
| Ms. Lisa Wyman M.S. | Chief Technical & Quality Officer | 1978 |
| Mr. Mo Qatanani Ph.D. | Chief Scientific Officer | 1973 |
| Ms. Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations | — |
| Ms. Junlin Ho J.D. | General Counsel & Corporate Secretary | 1979 |
| Ms. Caryn Parlavecchio | Chief Human Resources Officer | 1972 |
Fundamentals
Valuation
Market cap$5.92B
Price-to-sales ratioN/A
Price-to-book value23.33
Price-earnings ratio-14.50
Return on Equity-164.00%
Return on SalesN/A
Return on Assets-97.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.32
Income Statement
Average volume2,076,228
EBITDA$-394.19M
1 year high (52w)$61.76
1 year low (52w)$27.07
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
10 Wall Street Analyst Ratings
BUY
90% Buy
10% Hold
0% Sell
Target price
$70.30
Est return
44.56%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +5.3 | -17.8 | -1.3 | -2.1 | ||||||||
| 2022 | -27.8 | -6.5 | -23.8 | -47.3 | -34.3 | +17.8 | +28.7 | +32.8 | -20.3 | +37.7 | -16.1 | +15.0 |
| 2023 | +26.3 | -29.8 | -6.7 | -24.2 | -12.6 | +28.0 | -3.9 | -8.8 | +12.9 | +80.4 | +2.4 | +39.8 |
| 2024 | -20.3 | +3.7 | +13.3 | -12.6 | -37.2 | -12.1 | +11.7 | +2.6 | -12.0 | +281.7 | +40.4 | +13.9 |
| 2025 | -8.6 | -3.1 | -11.3 | +9.5 | -11.4 | +19.0 | +9.7 | -10.2 | +12.4 | -14.6 | +53.1 | +4.9 |
| 2026 | +3.6 | -5.0 | +13.1 | -5.6 | +6.3 | +16.1 | -10.5 | +23.9 | -13.0 |



